Literature DB >> 29334232

Stereotactic body radiation therapy (SBRT) for hepatocellular carcinoma: imaging evaluation post treatment.

Trenton Kellock1, Teresa Liang1, Alison Harris2, Devin Schellenberg3, Roy Ma3, Stephen Ho2, Wan Wan Yap4.   

Abstract

Surgical resection, when feasible, is the standard of care for hepatocellular carcinoma. However, many tumours are not resectable at the time of diagnosis. Recently, stereotactic body radiation therapy (SBRT) has emerged as a non-invasive local therapy for both non-resectable primary hepatic malignancies as well as hepatic metastases. Knowledge of the expected hepatic parenchymal appearance post treatment, as well as potential pitfalls and complications, is essential for accurate evaluation of treatment response. This pictorial review provides a fundamental description of the SBRT technique, outlines the expected cross-sectional imaging appearances of tumour response, and highlights potential pitfalls in interpretation. The expected liver parenchymal changes post-SBRT are also reviewed, along with some common radiation-induced complications.

Entities:  

Mesh:

Year:  2018        PMID: 29334232      PMCID: PMC6190776          DOI: 10.1259/bjr.20170118

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  13 in total

Review 1.  Three-dimensional conformal radiation therapy in the liver: MRI findings along a time continuum.

Authors:  Chandana Lall; Puneet Bhargava; Kumaresan Sandrasegaran; Alampady K Shanbhogue; Nilam Ramsinghani; Young Whan Koh; Jin Young Choi; Joon-Il Choi
Journal:  J Comput Assist Tomogr       Date:  2015 May-Jun       Impact factor: 1.826

Review 2.  Radiation therapy for liver tumors: ready for inclusion in guidelines?

Authors:  Shyam K Tanguturi; Jennifer Y Wo; Andrew X Zhu; Laura A Dawson; Theodore S Hong
Journal:  Oncologist       Date:  2014-07-07

Review 3.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

4.  Positron emission tomography scanning in the evaluation of hepatocellular carcinoma.

Authors:  M A Khan; C S Combs; E M Brunt; V J Lowe; M K Wolverson; H Solomon; B T Collins; A M Di Bisceglie
Journal:  J Hepatol       Date:  2000-05       Impact factor: 25.083

5.  Stereotactic body radiation therapy for liver metastases and primary hepatocellular carcinoma: normal tissue tolerances and toxicity.

Authors:  Stephen M Sawrie; John B Fiveash; Jimmy J Caudell
Journal:  Cancer Control       Date:  2010-04       Impact factor: 3.302

6.  Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma.

Authors:  Tracy R Price; Susan M Perkins; Kumar Sandrasegaran; Mark A Henderson; Mary A Maluccio; Jennifer E Zook; A Joseph Tector; Rodrigo M Vianna; Peter A S Johnstone; Higinia R Cardenes
Journal:  Cancer       Date:  2011-10-24       Impact factor: 6.860

7.  CT perfusion imaging in response assessment of pulmonary metastases undergoing stereotactic ablative radiotherapy.

Authors:  Brooke Sawyer; Emma Pun; Michael Samuel; Huilee Tay; Tomas Kron; Mathias Bressel; David Ball; Shankar Siva
Journal:  J Med Imaging Radiat Oncol       Date:  2015-01-20       Impact factor: 1.735

8.  18F-FDG PET and combined 18F-FDG-contrast CT parameters as predictors of tumor control for hepatocellular carcinoma after stereotactic ablative radiotherapy.

Authors:  Wen-Yen Huang; Chia-Hung Kao; Wen-Sheng Huang; Chang-Ming Chen; Li-Ping Chang; Meei-Shyuan Lee; Hsing-Lung Chao; Chuang-Hsin Chiu; Cheng-Hsiang Lo; Yee-Min Jen
Journal:  J Nucl Med       Date:  2013-08-22       Impact factor: 10.057

9.  CT Imaging Findings after Stereotactic Radiotherapy for Liver Tumors.

Authors:  Olga R Brook; Eavan Thornton; Mishal Mendiratta-Lala; Anand Mahadevan; Vassilious Raptopoulos; Alexander Brook; Robert Najarian; Robert Sheiman; Bettina Siewert
Journal:  Gastroenterol Res Pract       Date:  2015-06-29       Impact factor: 2.260

10.  Stereotactic body radiotherapy-induced arterial hypervascularity of non-tumorous hepatic parenchyma in patients with hepatocellular carcinoma: potential pitfalls in tumor response evaluation on multiphase computed tomography.

Authors:  Mee Jin Park; So Yeon Kim; Sang Min Yoon; Jong Hoon Kim; Seong Ho Park; Seung Soo Lee; Yedaun Lee; Moon-Gyu Lee
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

View more
  5 in total

1.  Characterization and Prediction of Signal Intensity Changes in Normal Liver Parenchyma on Gadoxetic Acid-enhanced MRI Scans after Liver-directed Radiation Therapy.

Authors:  Anthony D Nehlsen; Kunal K Sindhu; Thomas Wolken; Fahad Khan; Christopher K Kyriakakos; Stephen C Ward; Erin Moshier; Bachir Taouli; Michael Buckstein
Journal:  Radiol Imaging Cancer       Date:  2022-07

2.  The α-RECIST (RECIST 1.1 Combined With Alpha Fetoprotein): A Novel Tool for Identifying Tumor Response of Conversion-Radiotherapy for Unresectable Hepatocellular Carcinoma Before Hepatectomy.

Authors:  Ying Xu; Yi Yang; Lu Li; Feng Ye; Xinming Zhao
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

3.  Pathological Appearance of Focal Liver Reactions after Radiotherapy for Hepatocellular Carcinoma.

Authors:  Masahiro Okada; Kazushi Numata; Hiromi Nihonmatsu; Kengo Tomita; Atsuya Takeda; Kenichiro Tago; Tomoko Hyodo; Takahisa Eriguchi; Masayuki Nakano
Journal:  Diagnostics (Basel)       Date:  2022-04-25

4.  Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0-B1 hepatocellular carcinoma.

Authors:  Feiqian Wang; Kazushi Numata; Atsuya Takeda; Katsuaki Ogushi; Hiroyuki Fukuda; Koji Hara; Makoto Chuma; Takahisa Eriguchi; Yuichirou Tsurugai; Shin Maeda
Journal:  PLoS One       Date:  2021-01-05       Impact factor: 3.240

5.  Utility of Radiomics for Predicting Patient Survival in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis Treated With Stereotactic Body Radiotherapy.

Authors:  Kui Wu; Yongjie Shui; Wenzheng Sun; Sheng Lin; Haowen Pang
Journal:  Front Oncol       Date:  2020-10-14       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.